SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

05 Aug 2024 Evaluate
The sales moved down -73.51% to Rs. 10.06 millions for the June 2024 quarter as compared to Rs. 37.97 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2024 is Rs. -76.66 millions as compared to Net Loss of Rs. -28.70 millions of corresponding quarter ended June 2023 Operating profit Margin for the quarter ended June 2024 further decreased to -61.57% as compared to -11.55% of corresponding quarter ended June 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 10.06 37.97 -73.51 10.06 37.97 -73.51 116.93 135.39 -13.63
Other Income 39.31 56.40 -30.30 39.31 56.40 -30.30 211.30 84.49 150.09
PBIDT -61.57 -11.55 433.07 -61.57 -11.55 433.07 -98.07 -192.95 -49.17
Interest 0.23 0.51 -54.90 0.23 0.51 -54.90 1.58 2.89 -45.33
PBDT -61.80 -12.06 412.44 -61.80 -12.06 412.44 -25.08 -135.84 -81.54
Depreciation 14.86 16.64 -10.70 14.86 16.64 -10.70 65.02 65.43 -0.63
PBT -76.66 -28.70 167.11 -76.66 -28.70 167.11 -90.10 -201.27 -55.23
TAX 0.00 0.00 0.00 0.00 0.00 0.00 -10.02 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -76.66 -28.70 167.11 -76.66 -28.70 167.11 -80.08 -201.27 -60.21
Equity 218.07 218.07 0.00 218.07 218.07 0.00 218.07 218.07 0.00
PBIDTM(%) -612.03 -30.42 1912.01 -612.03 -30.42 1912.01 -83.87 -142.51 -41.15

Suven Life Sciences Share Price

210.80 14.90 (7.61%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×